The mechanism of action of estrogen in castration-resistant prostate cancer: Clues from hormone levels

Clinical Genitourinary Cancer

Volumn 7, Issue 3, 2009, Pages

  Aggarwal, Rahul ^a   Weinberg, Vivian ^a   Small, Eric J ^a   Oh, William ^b   Rushakoff, Robert ^a   Ryan, Charles J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Adrenal androgens; Castration resistance; Hormone levels; Secondary hormonal therapy

Indexed keywords

ANDROSTANOLONE; ANDROSTENEDIONE; DIETHYLSTILBESTROL; ESTRADIOL; ESTRONE; PC SPES; PRASTERONE; PRASTERONE SULFATE; PROSTATE SPECIFIC ANTIGEN; SEX HORMONE BINDING GLOBULIN; TESTOSTERONE; WARFARIN;

ADULT; AGED; ANDROSTENEDIONE BLOOD LEVEL; ARTICLE; CANCER GROWTH; CANCER HORMONE THERAPY; CASTRATION RESISTANT PROSTATE CANCER; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; ESTRADIOL BLOOD LEVEL; ESTROGEN THERAPY; ESTRONE BLOOD LEVEL; FOLLOW UP; HUMAN; MALE; PROSTATE CANCER; SEX HORMONE DETERMINATION; TESTOSTERONE BLOOD LEVEL; THROMBOEMBOLISM; THROMBOSIS PREVENTION; TREATMENT OUTCOME;

EID: 70449092017     PISSN: 15587673     EISSN: None     Source Type: Journal    
DOI: 10.3816/CGC.2009.n.027     Document Type: Article

References (26)

1. Huggins C, Hodges CV. Studies on prostatic cancer, effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1941; 1:293-297
2. El-Rayes BF, Hussain MH. Hormonal therapy for prostate cancer: past, present and future. Expert Rev Anticancer Ther 2002; 2:37-47.
3. Hellerstedt BA, Pienta KJ. The current state of hormonal therapy for prostate cancer. CA Cancer J Clin 2002; 52:154-179
4. Arnold JT, Blackman MR. Does DHEA exert direct effects on androgen and estrogen receptors, and does it promote or prevent prostate cancer? Endocrinology 2005; 146:4565-4567
5. Small E, Halabi S, Dawson NA, et al. Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583). J Clin Oncol 2004; 22:1025-1033
6. Ryan CJ, Halabi S, Ou SS, et al. Adrenal androgen levels as predictors of outcome in prostate cancer patients treated with ketoconazole plus antiandrogen withdrawal: results from a cancer and leukemia group B study. Clin Cancer Res 2007; 13:2030-2037
7. Takezawa Y, Nakata S, Kobayashi M, et al. Moderate dose diethylstilbestrol diphosphate therapy in hormone refractory prostate cancer. Scand J Urol Nephrol 2001; 35:283-287
8. Kitahara S, Umeda H, Yano M, et al. Effects of intravenous administration of high dose-diethylstilbestrol diphosphate on serum hormonal levels in patients with hormone-refractory prostate cancer. Endocr J 1999; 46:659-664
9. DiPaola RS, Zhang H, Lambert GH, et al. Clinical and biologic activity of an estrogenic herbal combination (PC-SPES) in prostate cancer. N Engl J Med 1998; 339:785-791
10. Oh WK, George DJ, Hackmann K, et al. Activity of the herbal combination, PCSPES, in the treatment of patients with androgen-independent prostate cancer. Urology 2001; 57:122-126
11. Small E, Frohlich MW, Bok R, et al. Prospective trial of the herbal supplement PCSPES in patients with progressive prostate cancer. J Clin Oncol 2000; 18:3595-3603
12. Oh WK, Kantoff PW, Weinberg V, et al. Prospective, multicenter, randomized phase II trial of the herbal supplement, PC-SPES, and diethylstilbestrol in patients with androgen-independent prostate cancer. J Clin Oncol 2004; 22:3705-3712
13. Bubley GJ, Carducci M, Dahut W, et al. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the PSA Working Group. J Clin Oncol 1999; 17:3461-3467
14. Pomerantz M, Manola J, Taplin ME, et al. Phase II study of low dose and high dose conjugated estrogen for androgen independent prostate cancer. J Urol 2007; 177:2146-2150
15. Vihko P, Herrala A, Harkonen P, et al. Control of cell proliferation by steroids: the role of 17HSDs. Mol Cell Endocrinol 2006; 248:141-148
16. Castagnetta L, Granata OM, Polito L, et al. Different conversion metabolic rates of testosterone are associated to hormone-sensitive status and response of human prostate cancer cells. J Steroid Biochem Mol Biol 1994; 49:351-357
17. Mostaghel E, Page ST, Lin DW, et al. Intraprostatic androgens and androgen-regulated gene expression persist after testosterone suppression: therapeutic implications for castration-resistant prostate cancer. Cancer Res 2007; 67:5033-5041
18. Stanbrough M, Bubley GJ, Ross K, et al. Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res 2006; 66:2815-2825
19. Titus MA, Gregory CW, Ford OH III, et al. Steroid 5alpha-reductase isozymes I and II in recurrent prostate cancer. Clin Cancer Res 2005; 11:4365-4371
20. Soronen P, Laiti M, Torn S, et al. Sex steroid hormone metabolism and prostate cancer. J Steroid Biochem Mol Biol 2004; 92:281-286
21. Malkowicz SB. The role of diethylstilbestrol in the treatment of prostate cancer. Urology 2001; 58(suppl 1):108-113
22. Robertson CN, Roberson KM, Padilla GM, et al. Induction of apoptosis by diethylstilbestrol in hormone-insensitive prostate cancer cells. J Natl Cancer Inst 1996; 88:908-917
23. Schulz P, Link TA, Chaudhuri L, et al. Role of the mitochondrial bc1-complex in the cytotoxic action of diethylstilbestrol-diphosphate toward prostatic carcinoma cells. Cancer Res 1990; 50:5008-5012
24. Schneider MR, Hartmann RW, Sinowatz F, et al. Nonsteroidal antiestrogens and partial estrogens with prostatic tumor inhibiting activity. J Cancer Res Clin Oncol 1986; 112:258-265
25. Loose-Mitchell D, Stancel GM. Estrogens and progestins. In: Hardman JG, Limbird L, Gilman A, eds. Goodman and Gilman's: The Pharmacological Basics of Therapeutics. New York: McGraw-Hill; 2001.
26. Ryan CJ, Beer TM. Prostate specific antigen only androgen independent prostate cancer: natural history, challenges in management and clinical trial design. J Urol 2007; 178:S25-9.